Secondary Stroke Prevention: Who Can Benefit from Device Therapies?
Presenters: Jamie Masjuan, Rolf Wachter, Matthias Endres, Jens Erik Nielsen-Kudsk
Panelist: George Ntaios
Volume 7 Issue 2 January 2022, pages 31-41
Received 12th December 2021; Accepted 15th December 2021
Jaime Masjuan – Hospital Universitario Ramon y Cajal, Madrid, Spain.
Rolf Wachter – Leipzig University Hospital, Leipzig, Germany.
Matthias Endres – Charité Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany.
Jens Erik Nielsen- Kudsk – Aarhus University Hospital, Skejby, Denmark.
George Ntaios – Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
This article is based on a symposium sponsored by Abbott that took place at ESOC 2021 on Friday 3rd of September 2021. The experts presenting in this symposium focused first on how to identify high-risk patients with cryptogenic stroke that can benefit from patent foramen ovale (PFO) closure and the clinical implications of the procedure. In the second part, they concentrated on discussing how to identify the patients with atrial fibrillation at high-risk of bleeding and reducing that risk while still preventing stroke through left atrium appendage occlusion (LAAO) and the clinical implications of this procedure. Data from several trials reveal how medical devices for PFO closure and LAAO improve patient outcomes. New trials are soon expected to contribute more valuable information.
Keywords:ANTICOAGULATION, ATRIAL FIBRILLATION, LEFT ATRIAL APPENDAGE, PATENT FORAMEN OVALE
Keep up to date with our latest
articles and journals